Processa Pharmaceuticals Inc (PCSA) concluded trading on Wednesday at a closing price of $0.30, with 50.61 million shares of worth about $15.18 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -78.10% during that period and on April 03, 2025 the price saw a loss of about -27.18%. Currently the company’s common shares owned by public are about 5.27M shares, out of which, 4.59M shares are available for trading.
Stock saw a price change of -23.39% in past 5 days and over the past one month there was a price change of -38.81%. Year-to-date (YTD), PCSA shares are showing a performance of -66.06% which decreased to -87.23% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.36 but also hit the highest price of $3.31 during that period. The average intraday trading volume for Processa Pharmaceuticals Inc shares is 235.72K. The stock is currently trading -29.55% below its 20-day simple moving average (SMA20), while that difference is down -43.29% for SMA50 and it goes to -73.79% lower than SMA200.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) currently have 5.27M outstanding shares and institutions hold larger chunk of about 1.88% of that.
The stock has a current market capitalization of $1.58M and its 3Y-monthly beta is at 1.31. It has posted earnings per share of -$3.89 in the same period. It has Quick Ratio of 1.22 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PCSA, volatility over the week remained 30.57% while standing at 15.59% over the month.
Stock’s fiscal year EPS is expected to rise by 75.19% while it is estimated to increase by 10.42% in next year. EPS is likely to grow at an annualized rate of 42.65% for next 5-years, compared to annual growth of 22.65% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on April 25, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it.
